Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers

By  

Current Pharmaceutical Design, Vol. 19, Iss. 42, 2013-12 ,pp. : 7479-7485

Bentham Science Publishers

Access to resources Recommend Favorite

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma

By Wong Chi   Loong Herbert   Hui Connie   Lau Cecilia   Hui Edwin   Ma Brigette   Chan Anthony  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1399-1408

Springer Publishing Company

Access to resources Recommend Favorite

Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 10, Iss. 2, 2011-03 ,pp. : 215-234

Bentham Science Publishers

Access to resources Recommend Favorite

Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans

By Almeida L.   Soares-da-Silva P.  

Drugs in R&D, Vol. 4, Iss. 5, 2003-01 ,pp. : 269-284

Adis International

Access to resources Recommend Favorite

Reduction of myocardial injury by the EP 3 receptor agonist TEI-3356. Role of protein kinase C and of K ATP -channels

By Zacharowski K.   Olbrich A.   Thiemermann C.  

European Journal of Pharmacology, Vol. 367, Iss. 1, 1999-02 ,pp. : 33-39

Elsevier

Access to resources Recommend Favorite